Nephrology and Urology· Topic 9.6 Evaluation of hematuria and stone disease· 9.6.5

Alport syndrome

Alport syndrome (hereditary nephritis) is a genetic type IV collagen disorder causing progressive glomerulonephritis with sensorineural hearing loss and ocular abnormalities, most often X-linked, that progresses to end-stage kidney disease in nearly all affected males. Management is supportive with renin-angiotensin system blockade to slow progression; there is no disease-specific therapy.

13 min read6 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    A hereditary glomerular disease from defective type IV collagen: Alport syndrome (hereditary nephritis) is a genetic disorder of the α3, α4, and α5 chains of type IV collagen, an integral structural…

  • Epidemiology

    A recognized cause of hereditary glomerulonephritis identified through family history, genetic testing, or biopsy in patients presenting with unexplained persistent hematuria.

  • Risk factors

    Family history of kidney failure, hematuria, or unexplained deafness: the single most important risk indicator, given the hereditary basis of the disease.

  • Pathophysiology

    Structural defect in the type IV collagen network of the GBM: most patients have a mutation in COL4A5 (encoding the α5 chain of type IV collagen), and more than 50% of all Alport syndrome patients…

  • Clinical features

    Classic presentation is a boy younger than 10 years with gross hematuria following a recent upper respiratory infection, often with a positive family history of kidney failure or hearing loss.

  • Differential diagnosis

    Thin basement membrane nephropathy (benign familial hematuria): isolated glomerular hematuria with normal blood pressure and usually no significant proteinuria, a uniformly thin GBM (typically <250…

  • Diagnosis

    First, establish the diagnosis by genetic testing identifying a pathogenic COL4A3, COL4A4, or COL4A5 variant, or by kidney biopsy with electron microscopy showing the basket-weave (lamellar)…

  • Management

    There is no disease-specific or curative therapy; management is supportive and aimed at slowing progression to ESKD.

  • Complications

    Progressive kidney failure to ESKD: occurs in virtually all affected males, often between the late teenage years and the fourth decade of life, and in some women, typically after age 50 years.

  • Prognosis

    Nearly all affected males progress to ESKD, most often between age 16 and 35 years, with the rate of progression fairly consistent within a given family but variable between families depending on the specific mutation.

  • Prevention

    Genetic counseling for families with a known COL4A3, COL4A4, or COL4A5 mutation before pregnancy, to discuss inheritance risk (X-linked, autosomal recessive, or autosomal dominant depending on the family's variant).

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.